Skip to main content
SpringerLink
Log in

Ropinirole in the Treatment of Parkinson’s Disease

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 188 Accesses

Abstract

Ropinirole is a synthesized non-ergotamic dopamine receptor agonist. It has an affinity to D2 and D3 dopamine receptors. It also has a partial affinity to 5-HT1a receptor as pramipexole. The affinity of ropinirole to the D3 receptor is 20 times larger compared to the D2 receptor. It does not have an affinity to the D1 receptor.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Chaudhuri KR, Martinez-Martin P, Rolfe KA, Cooper J, Rockett CB, Giorgi L, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012;19:105–13.

    Article  Google Scholar 

  • Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840–4.

    Article  Google Scholar 

  • Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, et al. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22:2409–17.

    Article  Google Scholar 

  • Kurin M, Bielefeldt K, Levinthal DJ. Prevalence of nausea and vomiting in adults using Ropinirole: a systematic review and meta-analysis. Dig Dis Sci. 2018;63:687–93.

    Article  CAS  Google Scholar 

  • Lai KL, Fang Y, Han H, Li Q, Zhang S, Li HY, et al. Orally-dissolving film for sublingual and buccal delivery of ropinirole. Colloids Surf B Biointerfaces. 2018;163:9–18.

    Article  CAS  Google Scholar 

  • Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, STRONG Study Group, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: STRONG study. Mov Disord. 2007;22:1860–5.

    Article  Google Scholar 

  • Montastruc JL, Brefel-Courbon C, Senard JM, Bagheri H, Ferreira J, Rascol O, et al. Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study. Clin Neuropharmacol. 2001;24:181–3.

    Article  CAS  Google Scholar 

  • Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174:1930–3.

    Article  Google Scholar 

  • Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, EASE-PD Adjunct Study Investigators, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68:1108–15.

    Article  CAS  Google Scholar 

  • Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, 056 Study Group, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21:1844–50.

    Article  Google Scholar 

  • Reichmann H, Cooper J, Rolfe K, Martinez-Martin P. Sleep duration and “on” time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive Ropinirole prolonged release. Parkinson’s Dis. 2011;2011:354760. https://doi.org/10.4061/2011/354760.

    Article  CAS  Google Scholar 

  • Schrag A, Keens J, Warner J, Ropinirole Study Group. Ropinirole for the treatment of tremor in early Parkinson’s disease. Eur J Neurol. 2002;9:253–7.

    Article  CAS  Google Scholar 

  • Singh ND, Banga AK. Controlled delivery of ropinirole hydrochloride through skin using modulated iontophoresis and microneedles. J Drug Target. 2013;21:354–66.

    Article  CAS  Google Scholar 

  • Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008;24:2883–95.

    Article  CAS  Google Scholar 

  • Stocchi F, Giorgi L, Hunter B, Schapira AH. PREPARED: comparison of prolonged and immediate release ropinirole in advanced Parkinson’s disease. Mov Disord. 2011;26:1259–65.

    Article  Google Scholar 

  • Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, REAL-PET Study Group, et al. Slower progression of Parkinson’s disease with Ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101.

    Article  CAS  Google Scholar 

  • Zhang Z, Wang J, Zhang X, Chen S, Wang Z, Zhang B, et al. The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson’s disease: a multicenter, double-blind, randomized, placebo-controlled study. Parkinsonism Relat Disord. 2013;19:1022–6.

    Article  Google Scholar 

  • Zhou CQ, Lou JH, Zhang YP, Zhong L, Chen YL, Lu FJ, et al. Long-acting versus standard non-ergot dopamine agonists in Parkinson’s disease: a meta-analysis of randomized controlled trials. CNS Neurosci Ther. 2014;20:368–76.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physical Therapy, Faculty of Health Science, Osaka Yukioka College of Health Science, Ibaraki City, Osaka, Japan

    Kuni Konaka

  2. Department of Neurology, Osaka University Graduate School of Medicine, Suita City, Osaka, Japan

    Kuni Konaka & Hideki Mochizuki

Authors
  1. Kuni Konaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideki Mochizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideki Mochizuki .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Konaka, K., Mochizuki, H. (2020). Ropinirole in the Treatment of Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_235-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_235-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation